Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Sera Prognostics, Inc.NASDAQ: SERA

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash declines year over year

Q1 FY2026 net change in cash of $231K fell 80.5% year over year, ahead of the -206.5% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -85.0% a year.

Context

  • Net change in cash amounted to 122.2% of revenue in FY2025, down 89.5 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -80.5% holds above the trailing-twelve-month pace of -206.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$231K+268.6% QoQ
Last fiscal yearDec 2025
-$99K-160.7% YoY
LTMMar 2026
-$1.06M-206.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.5%——
1 year-160.7%——
3-year CAGR-85.0%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(99K) USD
Year-over-year change
-160.7%

Net Change in Cash vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -206.5% is the lowest of 8, against a peer median of +47.7%.
  • Net change in cash amounts to 1850.9% of revenue for SERA, versus a peer median of 51.4%.
SERA Competitors
Net Change in Cash for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGTXCognition Therapeutics, Inc.LTM Mar 2026$14.8M USD+181.1%——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$7.58M CAD-47.0%-35.2%—
SRZNSurrozen, Inc.LTM Mar 2026$5.27M USD-92.9%—70.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$5.09M USD+47.7%—14.8%
LUCDLucid Diagnostics Inc.LTM Mar 2026$2.64M USD+462.5%—51.4%
SERASera Prognostics, Inc.LTM Mar 2026$1.06M USD-206.5%-85.0%1850.9%
STSSSkyAI, Inc.LTM Mar 2026$336.9K USD-96.9%+51.6%84.9%
APYXApyx Medical CorporationLTM Mar 2026$126K USD+102.0%-96.4%0.2%
HURATuHURA Biosciences, Inc.LTM Mar 2026$78.3K USD———
Peer median (excluding SERA) —+47.7%-35.2%51.4%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Depreciation & Amortization659K756K900K833K940K
Deferred Income Tax00000
Stock-Based Compensation3.13M5.06M5.27M7.01M5.11M
Change in Working Capital(44K)3.55M3.52M11.28M(546K)
Accounts Receivables(3.14M)(2.97M)(5.36M)11.42M22K
Inventory00000
Accounts Payables603K352K(442K)455K(1.01M)
Other Working Capital2.49M6.17M9.32M(597K)441K
Other Non-Cash Items(372K)213K(638K)(412K)801K
Operating Cash Flow(31.64M)(34.61M)(27.19M)(14.19M)(25.62M)
Capital Expenditures(1.3M)(791K)(128K)(1.1M)(726K)
Acquisitions (Net)00000
Purchases of Investments(82.06M)(48.07M)(54.14M)(35.83M)(87.61M)
Sales of Investments800K54.4M54.4M48.68M59.84M
Other Investing Activities016K311K(1.05M)0
Investing Cash Flow(82.56M)5.55M438K11.74M(28.5M)
Debt Repayment(7.66M)(303K)(466K)(440K)(194K)
Common Stock Issued66.61M00054.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.66M308K1.22M3.05M0
Financing Cash Flow159.59M5K752K2.61M54.03M
Effect of Forex Changes00000
Net Change in Cash45.4M(29.05M)(26M)163K(99K)
Free Cash Flow(32.94M)(35.4M)(27.32M)(15.29M)(26.35M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.